Leukemia Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

  • ID: 4315763
  • Report
  • 187 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Acobiom
  • CeMines, Inc.
  • Health Discovery Corp
  • Monoquant Pty. Ltd.
  • SkylineDx BV
  • University of Colorado
  • MORE
Leukemia Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Summary

The analyst's Medical Devices sector report, “Leukemia Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Leukemia Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Leukemia Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Leukemia Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Leukemia Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Leukemia Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acobiom
  • CeMines, Inc.
  • Health Discovery Corp
  • Monoquant Pty. Ltd.
  • SkylineDx BV
  • University of Colorado
  • MORE
1 Table of Contents
2 Introduction
2.1 Leukemia Diagnostic Tests Overview
3 Products under Development
3.1 Leukemia Diagnostic Tests - Pipeline Products by Stage of Development
3.2 Leukemia Diagnostic Tests - Pipeline Products by Territory
3.3 Leukemia Diagnostic Tests - Pipeline Products by Regulatory Path
3.4 Leukemia Diagnostic Tests - Pipeline Products by Estimated Approval Date
4 Leukemia Diagnostic Tests - Pipeline Products under Development by Companies
4.1 Leukemia Diagnostic Tests Companies - Pipeline Products by Stage of Development
4.2 Leukemia Diagnostic Tests - Pipeline Products by Stage of Development
5 Leukemia Diagnostic Tests Companies and Product Overview
5.1 Acobiom Company Overview
5.1.1 Acobiom Pipeline Products & Ongoing Clinical Trials Overview
5.2 Aegis Sciences Corp Company Overview
5.2.1 Aegis Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview
5.3 BioSense Technologies, Inc. Company Overview
5.3.1 BioSense Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.4 Cancer Genetics Inc Company Overview
5.4.1 Cancer Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.5 Cell2in Company Overview
5.5.1 Cell2in Pipeline Products & Ongoing Clinical Trials Overview
5.6 CeMines, Inc. (Inactive) Company Overview
5.6.1 CeMines, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.7 Cepheid Company Overview
5.7.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview
5.8 Di.V.A.L Toscana srl Company Overview
5.8.1 Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview
5.9 DiaSorin S.p.A Company Overview
5.9.1 DiaSorin S.p.A Pipeline Products & Ongoing Clinical Trials Overview
5.10 Eutropics Pharmaceuticals Inc Company Overview
5.10.1 Eutropics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
5.11 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview
5.11.1 H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
5.12 Health Discovery Corp Company Overview
5.12.1 Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview
5.13 IV Diagnostics, Inc. Company Overview
5.13.1 IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.14 Jaden BioScience Inc. Company Overview
5.14.1 Jaden BioScience Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.15 King's College London Company Overview
5.15.1 King's College London Pipeline Products & Ongoing Clinical Trials Overview
5.16 Microfluidic Innovations LLC Company Overview
5.16.1 Microfluidic Innovations LLC Pipeline Products & Ongoing Clinical Trials Overview
5.17 Monoquant Pty. Ltd. Company Overview
5.17.1 Monoquant Pty. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.18 Nodality Inc Company Overview
5.18.1 Nodality Inc Pipeline Products & Ongoing Clinical Trials Overview
5.19 NuCana BioMed Ltd Company Overview
5.19.1 NuCana BioMed Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.20 Nuclea Biotechnologies Inc. (Inactive) Company Overview
5.20.1 Nuclea Biotechnologies Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.21 OncoVista Innovative Therapies Inc Company Overview
5.21.1 OncoVista Innovative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.22 Roche Diagnostics International Ltd Company Overview
5.22.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.23 Siemens Healthcare GmbH Company Overview
5.23.1 Siemens Healthcare GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.24 SkylineDx BV Company Overview
5.24.1 SkylineDx BV Pipeline Products & Ongoing Clinical Trials Overview
5.25 St. Jude Children’s Research Hospital Inc Company Overview
5.25.1 St. Jude Children’s Research Hospital Inc Pipeline Products & Ongoing Clinical Trials Overview
5.26 Stanford University Company Overview
5.26.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview
5.27 The Feinstein Institute for Medical Research Company Overview
5.27.1 The Feinstein Institute for Medical Research Pipeline Products & Ongoing Clinical Trials Overview
5.28 Treos Bio Inc Company Overview
5.28.1 Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
5.29 University of Bergen Company Overview
5.29.1 University of Bergen Pipeline Products & Ongoing Clinical Trials Overview
5.30 University of California San Diego Company Overview
5.30.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
5.31 University of Colorado Company Overview
5.31.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview
5.32 University of Missouri Company Overview
5.32.1 University of Missouri Pipeline Products & Ongoing Clinical Trials Overview
5.33 University of Pennsylvania Company Overview
5.33.1 University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview
5.34 Vela Diagnostics Pte. Ltd Company Overview
5.34.1 Vela Diagnostics Pte. Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.35 Vivia Biotech SL Company Overview
5.35.1 Vivia Biotech SL Pipeline Products & Ongoing Clinical Trials Overview
5.36 Wake Forest Baptist Medical Center Company Overview
5.36.1 Wake Forest Baptist Medical Center Pipeline Products & Ongoing Clinical Trials Overview
6 Leukemia Diagnostic Tests - Recent Developments
6.1 Jun 06, 2017: BD Releases 2016 Sustainability Report
6.2 Jun 01, 2017: MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries
6.3 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy
6.4 May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter
6.5 May 02, 2017: Pfizer Reports First-Quarter 2017 Results
6.6 May 02, 2017: QIAGEN reports results for first quarter 2017
6.7 Apr 26, 2017: NeoGenomics Reports 15% Volume Growth and 10% Reduction in Average Cost per Test in the First Quarter of 2017
6.8 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
6.9 Apr 25, 2017: Laboratory Corporation of America Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance
6.10 Apr 23, 2017: BD Announces Appointment Of Tom Polen As President
6.11 Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK
6.12 Apr 20, 2017: NeoGenomics Appoints Bill Bonello as Vice President, Treasurer, and Director of Corporate Development
6.13 Apr 17, 2017: Dr. Frank Basile Joins Aegis Sciences as Chief Executive Officer
6.14 Mar 29, 2017: LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company’s Two Primary Business Segments
6.15 Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management
6.16 Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update
6.17 Mar 21, 2017: Retractable Technologies Announces Litigation Updates
6.18 Mar 13, 2017: Cancer Genetics to Present at “A Future Without Cancer Conference” on Friday, March 17
6.19 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
6.20 Feb 23, 2017: Ronald E. Blaylock Elected to Pfizer’s Board of Directors
6.21 Feb 22, 2017: NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016
6.22 Feb 16, 2017: Laboratory Corporation of America Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance
6.23 Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter
6.24 Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016
6.25 Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results
6.26 Jan 31, 2017: Kyowa Hakko Kirin Establishes Kyowa Kirin Frontier
6.27 Jan 30, 2017: Stephen Gottschalk, M.D., has been named chair of the Department of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children's Research Hospital
6.28 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
6.29 Jan 26, 2017: Achievement of sales milestone for COPD products
6.30 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
6.31 Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions
6.32 Dec 07, 2016: Stem cell-based test predicts leukemia patients' response to therapy to tailor treatment
6.33 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
6.34 Nov 21, 2016: Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire
6.35 Nov 10, 2016: Cancer Genetics Announces Strong Third Quarter with 68% Year over Year Revenue Growth and Highlights Path to Future Profitability
6.36 Nov 10, 2016: Diasorin Group Reports Continued Growth In Revenues And Profitability In The Third Quarter 2016
6.37 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance
6.38 Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016
6.39 Nov 02, 2016: QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial net sales and adjusted earnings guidance for 2017
6.40 Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results
6.41 Nov 01, 2016: Asuragen Launches QuantideX NGS RNA Lung Cancer Kit
6.42 Oct 28, 2016: Kyowa Hakko Kirin Announces Consolidated Financial Results for the First Nine Months Ended September 30, 2016
6.43 Oct 26, 2016: Laboratory Corporation of America Holdings Announces 2016 Third Quarter Results and Updates 2016 Guidance
6.44 Oct 26, 2016: NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016
6.45 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
6.46 Sep 26, 2016: Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
6.47 Sep 20, 2016: LabCorp Names Veteran Biopharma Executive John Ratliff CEO of Covance Drug Development
6.48 Sep 07, 2016: Pfizer Appoints Chief Scientific Officer for Neuroscience Research
6.49 Aug 09, 2016: Cancer Genetics Reports Second Quarter 2016 Financial Results and Provides Company Updates
6.50 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter
6.51 Aug 04, 2016: Diasorin Group Revenues And EBITDA Reached Record highs In the Second Quarter 2016
6.52 Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results
6.53 Aug 02, 2016: Kyowa Hakko Kirin Completed of Construction for the Biopharmaceutical API Manufacturing Facility in the Takasaki Plant
6.54 Jul 29, 2016: Kyowa Hakko Kirin Announces Consolidated Financial Results for the Six Months Ended June 30, 2016
6.55 Jul 28, 2016: QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017
6.56 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors
6.57 Jul 28, 2016: Cepheid Reports Second Quarter 2016 Results
6.58 Jul 27, 2016: Laboratory Corporation of America Holdings Announces 2016 Second Quarter Results and Raises 2016 Guidance
6.59 Jul 26, 2016: NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016
6.60 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
6.61 Jul 13, 2016: Pfizer and NovaMedica announce a strategic partnership in Russia
6.62 Jul 05, 2016: Biocept Granted Japanese Patent Covering Microchannel and Antibody Capture
6.63 Jul 04, 2016: Exiqon - Nomination of candidates for the supervisory board
6.64 Jun 30, 2016: Wake Forest Baptist Receives Specialty Pharmacy Accreditation
6.65 Jun 27, 2016: Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance
6.66 Jun 21, 2016: Rosetta Genomics Receives Approval from New York State for HEME FISH-based Assays
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Leukemia Diagnostic Tests - Pipeline Products by Stage of Development
Table 2: Leukemia Diagnostic Tests - Pipeline Products by Territory
Table 3: Leukemia Diagnostic Tests - Pipeline Products by Regulatory Path
Table 4: Leukemia Diagnostic Tests - Pipeline Products by Estimated Approval Date
Table 5: Leukemia Diagnostic Tests Companies - Pipeline Products by Stage of Development
Table 6: Leukemia Diagnostic Tests - Pipeline Products by Stage of Development
Table 7: Acobiom Pipeline Products & Ongoing Clinical Trials Overview
Table 8: Diagnostic Assay - Chronic Myelomonocytic Leukemia - Product Status
Table 9: Diagnostic Assay - Chronic Myelomonocytic Leukemia - Product Description
Table 10: Aegis Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 11: Diagnostic Assay - Leukemia - Product Status
Table 12: Diagnostic Assay - Leukemia - Product Description
Table 13: BioSense Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 14: Diagnostic Assay - BCR-ABL (+) - Product Status
Table 15: Diagnostic Assay - BCR-ABL (+) - Product Description
Table 16: Cancer Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 17: LeukA - Leukemia - Product Status
Table 18: LeukA - Leukemia - Product Description
Table 19: Cell2in Pipeline Products & Ongoing Clinical Trials Overview
Table 20: Diagnostic Test - Blood Cancer - Product Status
Table 21: Diagnostic Test - Blood Cancer - Product Description
Table 22: CeMines, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 23: Diagnostic Test For Leukemia - Product Status
Table 24: Diagnostic Test For Leukemia - Product Description
Table 25: Cepheid Pipeline Products & Ongoing Clinical Trials Overview
Table 26: XPERT CLL Monitoring Test - Product Status
Table 27: XPERT CLL Monitoring Test - Product Description
Table 28: Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview
Table 29: NanoMabKv - Leukemia - Product Status
Table 30: NanoMabKv - Leukemia - Product Description
Table 31: DiaSorin S.p.A Pipeline Products & Ongoing Clinical Trials Overview
Table 32: BCR-ABL P190 + ABL Assay - Product Status
Table 33: BCR-ABL P190 + ABL Assay - Product Description
Table 34: C-Kit 816 Assay - Product Status
Table 35: C-Kit 816 Assay - Product Description
Table 36: C-Kit 822 Assay - Product Status
Table 37: C-Kit 822 Assay - Product Description
Table 38: LIAISON IAM - Acute Lymphoblastic Leukemia Test - Product Status
Table 39: LIAISON IAM - Acute Lymphoblastic Leukemia Test - Product Description
Table 40: LIAISON IAM - Acute Promyelocytic Leukemia Test - Product Status
Table 41: LIAISON IAM - Acute Promyelocytic Leukemia Test - Product Description
Table 42: PML-RAR1 + ABL Assay - Product Status
Table 43: PML-RAR1 + ABL Assay - Product Description
Table 44: PML-RAR2 + ABL Assay - Product Status
Table 45: PML-RAR2 + ABL Assay - Product Description
Table 46: PML-RAR3 + ABL Assay - Product Status
Table 47: PML-RAR3 + ABL Assay - Product Description
Table 48: Eutropics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 49: EU-4030 Companion Diagnostic Assay - AML - Product Status
Table 50: EU-4030 Companion Diagnostic Assay - AML - Product Description
Table 51: EU-5013 Companion Diagnostic Assay - AML - Product Status
Table 52: EU-5013 Companion Diagnostic Assay - AML - Product Description
Table 53: PraediCare Alvocidib Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status
Table 54: PraediCare Alvocidib Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description
Table 55: PraediCareDx Companion Diagnostic Assay - Alvocidib - Product Status
Table 56: PraediCareDx Companion Diagnostic Assay - Alvocidib - Product Description
Table 57: H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Diagnostic Assay - Acute Myeloid Leukemia (AML) M5 Subtype - Product Status
Table 59: Diagnostic Assay - Acute Myeloid Leukemia (AML) M5 Subtype - Product Description
Table 60: Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 61: Diagnostic Test - Pre-Leukemia - Product Status
Table 62: Diagnostic Test - Pre-Leukemia - Product Description
Table 63: IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 64: Diagnostic Test - Leukemia - Product Status
Table 65: Diagnostic Test - Leukemia - Product Description
Table 66: Jaden BioScience Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 67: Ultrasensitive Assay - B-Cell Chronic Lymphocytic Leukemia - Product Status
Table 68: Ultrasensitive Assay - B-Cell Chronic Lymphocytic Leukemia - Product Description
Table 69: King's College London Pipeline Products & Ongoing Clinical Trials Overview
Table 70: PARPi Sensitivity Test - AML - Product Status
Table 71: PARPi Sensitivity Test - AML - Product Description
Table 72: Microfluidic Innovations LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 73: Companion Diagnostic Test - Chronic Myeloid Leukemia - Product Status
Table 74: Companion Diagnostic Test - Chronic Myeloid Leukemia - Product Description
Table 75: Monoquant Pty. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 76: PCR-Based Diagnostic Test - Chronic Myeloid Leukemia - Product Status
Table 77: PCR-Based Diagnostic Test - Chronic Myeloid Leukemia - Product Description
Table 78: Nodality Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 79: Acute Myeloid Leukemia Induction Response Test - Product Status
Table 80: Acute Myeloid Leukemia Induction Response Test - Product Description
Table 81: NuCana BioMed Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 82: NUC-10000 Companion Diagnostic Test - Product Status
Table 83: NUC-10000 Companion Diagnostic Test - Product Description
Table 84: NUC-11000 Companion Diagnostic Test - Product Status
Table 85: NUC-11000 Companion Diagnostic Test - Product Description
Table 86: NUC-12000 Companion Diagnostic Test - Product Status
Table 87: NUC-12000 Companion Diagnostic Test - Product Description
Table 88: NUC-6285 Companion Diagnostic Test - Product Status
Table 89: NUC-6285 Companion Diagnostic Test - Product Description
Table 90: NUC-7000 Companion Diagnostic Test - Product Status
Table 91: NUC-7000 Companion Diagnostic Test - Product Description
Table 92: NUC-8000 Companion Diagnostic Test - Product Status
Table 93: NUC-8000 Companion Diagnostic Test - Product Description
Table 94: Nuclea Biotechnologies Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 95: CML Detection Test - Product Status
Table 96: CML Detection Test - Product Description
Table 97: MLL Detection Test - Product Status
Table 98: MLL Detection Test - Product Description
Table 99: OncoVista Innovative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 100: OVI-123(Cordycepin) Biomarker - Leukemia - Product Status
Table 101: OVI-123(Cordycepin) Biomarker - Leukemia - Product Description
Table 102: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 103: Companion Diagnostic Test - Obinutuzumab - Product Status
Table 104: Companion Diagnostic Test - Obinutuzumab - Product Description
Table 105: Siemens Healthcare GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 106: Companion Diagnostic Test - Inotuzumab Ozogamicin - Product Status
Table 107: Companion Diagnostic Test - Inotuzumab Ozogamicin - Product Description
Table 108: SkylineDx BV Pipeline Products & Ongoing Clinical Trials Overview
Table 109: AMLProfiler - Product Status
Table 110: AMLProfiler - Product Description
Table 111: St. Jude Children’s Research Hospital Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 112: Biomarker Based Assay - MRD ALL - Product Status
Table 113: Biomarker Based Assay - MRD ALL - Product Description
Table 114: Diagnostic Assay - MRD In Leukemia - Product Status
Table 115: Diagnostic Assay - MRD In Leukemia - Product Description
Table 116: Stanford University Pipeline Products & Ongoing Clinical Trials Overview
Table 117: Anti-AF5 Monoclonal Antibody Assay - Product Status
Table 118: Anti-AF5 Monoclonal Antibody Assay - Product Description
Table 119: The Feinstein Institute for Medical Research Pipeline Products & Ongoing Clinical Trials Overview
Table 120: Prognostic Test - Chronic Lymphocytic Leukemia - Product Status
Table 121: Prognostic Test - Chronic Lymphocytic Leukemia - Product Description
Table 122: Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 123: PolyPEPI 513 CDx - Product Status
Table 124: PolyPEPI 513 CDx - Product Description
Table 125: University of Bergen Pipeline Products & Ongoing Clinical Trials Overview
Table 126: Prognostic Marker Test - Leukemia - Product Status
Table 127: Prognostic Marker Test - Leukemia - Product Description
Table 128: University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
Table 129: Biomarker Assay - Chronic Lymphocytic Leukemia - Product Status
Table 130: Biomarker Assay - Chronic Lymphocytic Leukemia - Product Description
Table 131: ROR1 Monoclonal Antibody Assay - Product Status
Table 132: ROR1 Monoclonal Antibody Assay - Product Description
Table 133: University of Colorado Pipeline Products & Ongoing Clinical Trials Overview
Table 134: Molecular Probe Assay - Acute Myeloid Leukemia - Product Status
Table 135: Molecular Probe Assay - Acute Myeloid Leukemia - Product Description
Table 136: University of Missouri Pipeline Products & Ongoing Clinical Trials Overview
Table 137: Multiple Methylation Sensitive Enzyme Restriction PCR (MSR-PCR) Assay - Product Status
Table 138: Multiple Methylation Sensitive Enzyme Restriction PCR (MSR-PCR) Assay - Product Description
Table 139: University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview
Table 140: xMELP Assay - Product Status
Table 141: xMELP Assay - Product Description
Table 142: Vela Diagnostics Pte. Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 143: Sentosa SQ Leukemia Panel - Product Status
Table 144: Sentosa SQ Leukemia Panel - Product Description
Table 145: Vivia Biotech SL Pipeline Products & Ongoing Clinical Trials Overview
Table 146: Personalized Medicine Test - Acute Lymphocytic Leukemia - Product Status
Table 147: Personalized Medicine Test - Acute Lymphocytic Leukemia - Product Description
Table 148: Personalized Medicine Test - Chronic Lymphocytic Leukemia - Product Status
Table 149: Personalized Medicine Test - Chronic Lymphocytic Leukemia - Product Description
Table 150: Wake Forest Baptist Medical Center Pipeline Products & Ongoing Clinical Trials Overview
Table 151: Diagnostic Assay - Acute Erythroid Leukemia - Product Status
Table 152: Diagnostic Assay - Acute Erythroid Leukemia - Product Description
Table 153: Glossary

List of Figures
Figure 1: Leukemia Diagnostic Tests - Pipeline Products by Stage of Development
Figure 2: Leukemia Diagnostic Tests - Pipeline Products by Territory
Figure 3: Leukemia - Pipeline Products by Regulatory Path
Figure 4: Leukemia Diagnostic Tests - Pipeline Products by Estimated Approval Date
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acobiom
  • Aegis Sciences Corp
  • BioSense Technologies, Inc.
  • Cancer Genetics Inc
  • Cell2in
  • CeMines, Inc.
  • Cepheid
  • Di.V.A.L Toscana srl
  • DiaSorin S.p.A
  • Eutropics Pharmaceuticals Inc
  • H. Lee Moffitt Cancer Center & Research Institute Inc
  • Health Discovery Corp
  • IV Diagnostics, Inc.
  • Jaden BioScience Inc.
  • King's College London
  • Microfluidic Innovations LLC
  • Monoquant Pty. Ltd.
  • Nodality Inc
  • NuCana BioMed Ltd
  • Nuclea Biotechnologies Inc.
  • OncoVista Innovative Therapies Inc
  • Roche Diagnostics International Ltd
  • Siemens Healthcare GmbH
  • SkylineDx BV
  • St. Jude Children’s Research Hospital Inc
  • Stanford University
  • The Feinstein Institute for Medical Research
  • Treos Bio Inc
  • University of Bergen
  • University of California San Diego
  • University of Colorado
  • University of Missouri
  • University of Pennsylvania
  • Vela Diagnostics Pte. Ltd
  • Vivia Biotech SL
  • Wake Forest Baptist Medical Center
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll